Silberstein S, Diamond M, Hindiyeh NA, et al. - For the prevention of chronic migraine, researchers characterized the therapeutic effects of eptinezumab 100 mg and 300 mg over the full 24-week treatment period of the pivotal PROMISE-2 trial, a phase 3, randomized, double-blind, placebo-controlled study. In the PROMISE-2 trial, repeat intravenous (IV) doses of the eptinezumab were administered for migraine prevention in 1,072 adults with chronic migraine. During the primary 12-week period of treatment in PROMISE-2, single doses of eptinezumab 100 mg and 300 mg were linked with significant decreases in the primary endpoint (mean monthly migraine days). In addition, the percentage of patients with a migraine decreased by over half on the day after the initial dose. Over 24 weeks of treatment, both doses (100 mg and 300 mg) offered statistically significant and clinically meaningful migraine preventive effects over multiple efficacy measures and the doses were well tolerated.